Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting
June 15, 2019 11:30 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 15, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial...
Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights
May 08, 2019 16:05 ET
|
Sunesis Pharmaceuticals, Inc.
Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sunesis...
Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights
May 01, 2019 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, May 8th, 2019 at 4:30...
Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank
April 29, 2019 16:05 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon...
Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference
April 03, 2019 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President,...
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
March 07, 2019 16:01 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2018....
Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences
March 04, 2019 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will participate in three upcoming investor conferences...
Sunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
February 28, 2019 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Thursday, March 7th, 2019 at 4:30...
Sunesis Announces Pricing of $20 Million Offering of Securities
January 17, 2019 21:58 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of...
Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock
January 17, 2019 16:05 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions,...